Skip to main content

Moderna, Inc Investor Event Transcript, Nov 18, 2026

Moderna, Inc. (MRNA)

Moderna says it is commercially ready for intismoran, with its BLA to be fully filed by year-end after a positive Phase III adjuvant melanoma study. The company cites 22,000 eligible U.S. patients under the Phase III criteria, and Merck will share profits 50-50 in the United States. Moderna also reports a balance sheet that is $9 billion strong at the end of this year, to fund oncology growth. AI summary

Investor Event Transcript 2026-11-18 For: 2026-12-31
Added on November 19, 2026

Conference Transcript - MRNA 2026-11-18

Andrew Tsai, Analyst — Jefferies

Okay. We're going to get started with our next session. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. Thank you for joining me today, and I have the pleasure to have the Moderna team with me. To my direct left is David Berman, Chief Development Officer, and to his left, Lavina Talukdar, Head of Investor Relations. Welcome, both of you.

David Berman, Other

Thank you for having us, Andrew.

Andrew Tsai, Analyst — Jefferies

Sure. Congratulations on the success that you've had so far with that Phase III INT melanoma data that was just shared at ESMO. As we think ahead into 2027, can you just walk us through the various milestones you would encourage investors to pay attention to? That would be helpful.

David Berman, Other

Yeah, Andrew, once again, thank you for inviting us here today. So for the rest of the year, I think there's two more data points. First is our 2808 T-cell engager myeloma data, which will be at ASH next month, and then a readout of our propionic acidemia pivotal trial. This is our first proof of confidence that we can develop an mRNA LMP for a metabolic disorder. Next year, or either towards the end of this year or into next year, So sometime in the next, you know, 12 or so months would be the RCC interim analysis data, and then MIBC data, final analysis, would be in 27 also.

Speaker 2

Both for intismoran.

Andrew Tsai, Analyst — Jefferies

Yeah, for intismoran. And would lung cancer, by chance, since you complete enrollment for one of them, be ready year end of 2027, possibly?

David Berman, Other

So it is event-driven. In theory, it could, but it could also be in 2028, so either 27 or 28.

Andrew Tsai, Analyst — Jefferies

Okay, very clear. I did want to spend a lot of the discussion on INT today, if you don't mind. So big picture, can you just remind us how big the TAM is for INT, starting with adjuvant melanoma, where you've succeeded in phase three, and then walk us through the next set of TAM. That would be very helpful.

Speaker 2

So we do believe that in Tizmoran is going to be a multibillion-dollar opportunity, but for now we've given the eligible population for adjuvant melanoma because that's where we have the positive Phase III study. And for that indication alone, in the U.S., it's 22,000 patients that are eligible based on our Phase III clinical trial inclusion criteria.

Andrew Tsai, Analyst — Jefferies

And then RCC, bladder, lung, how big would those be?

Speaker 2

So also multi-billion dollar opportunities. We have not yet given the eligible populations yet.

Andrew Tsai, Analyst — Jefferies

Okay, no problem. And so looking ahead, as we think about commercialization, because you're filing the BLA year-end, by year-end, this could be approved in second half, 2027. So speak to the commercial readiness. How much have you prepared? Are you ready to go on day one? Should this be approved?

Speaker 2

I'll start, and David, please fill in. You're right that we are advancing the BLA and hope to get it fully filed by the end of this year. We are commercial ready. Just last week, we hosted investors as well as analysts at our Marble facility, which is purpose-built for the Intis Moran product. It is not fully built out yet. We are using one suite, which is enough to get through commercialization for the melanoma setting, and we do plan to add on up to six additional suites as we see demand signals, and that to us is positive readouts from the very large development program that we have ongoing.

David Berman, Other

I'll just add a couple other points, Andrew. From a launch perspective, I think if you think about the drug profile, great efficacy and the adverse event profile is very mild. It's essentially just some fever, flu-like feeling. So from a patient-doctor experience on treatment, I think it should be very manageable and very favorable. I think for us, what we're focused on is the front-end part, which is teaching sites about obtaining the right amount of tissue and type of tissue and getting that then submitted for sequencing and for the drug product to be made. The good news is that we've been able to do this, obviously, in a randomized phase three, but now for thousands of patients globally. So we are optimistic that we'll be able to serve the launch appropriately. Right.

Andrew Tsai, Analyst — Jefferies

Through your clinical studies, you've already dosed 1,000. Plus patients.

Speaker 2

More than 2,000 patients. Okay. And when we're fully done with the clinical development program, we'll have enrolled 5,000 patients. So your question on being launch ready day one, we feel very optimistic that we are launch ready.

Andrew Tsai, Analyst — Jefferies

Okay. And then going back to the Marlboro site, I think you mentioned one suite is ready now. How much capacity is that? How many How many patients per year can that supply? And then you said six additional. So what's the total amount per year off of that single manufacturing site?

Speaker 2

So when we're fully built out, we'll be able to supply tens of thousands of patients from that one facility, but that's that full build out. We haven't said anything about the capacity from the one suite as we're continuing to do productivity and efficiency gains on the process itself. So it is a continual process that's ongoing.

Andrew Tsai, Analyst — Jefferies

I see. And then understood that this alone can probably handle globally, but are there other manufacturing sites that you've built out or are building out globally?

Speaker 2

So this facility we do think will have global reach. Just to remind everyone, the clinical trial program in adjuvant melanoma, as well as some of the other programs that are ongoing, has served 46 countries around the world, and we did that without a hitch. So we're very optimistic that this Marlboro facility on the east coast of the United States can actually do a global launch.

Andrew Tsai, Analyst — Jefferies

And speaking of efficiencies, I think one discussion point could be the turnaround time of INT. In the clinical studies, remind me how long that took. Where do you think that can get you to over time?

David Berman, Other

So in the clinical trials, it was about 63 days. But part of that was also because in the clinical trials, the intizmirin or placebo had to be matched to the date of the pembrolizumab infusion, which doesn't need to be the case. We know we've been able to get it down in a good situation to about 30 days, and I think about six weeks is something right now that is very achievable. So we will continue to bring down that turnaround time.

Andrew Tsai, Analyst — Jefferies

I see. And in terms of the manufacturing success rate, also remind us what that was in the clinical studies. Is there any need to be improved?

David Berman, Other

Yeah. So we have great success rate. Once we have adequate tumor, we have a very high success rate of identifying neoantigens. And then from a manufacturing point of view, it was over 99% successful. In fact, I think only one of the 700-plus patients in TISMIRAN randomized arm was not able to receive their drug product. So a very high, over 99% success rate of manufacturing.

Andrew Tsai, Analyst — Jefferies

I see. And then can you remind me the Merck partnership, this is a collaboration. To be clear, you're building out the drug supply. Is Merck selling it, and how does that work, U.S. and ex-U.S.?

Speaker 2

So the partnership with Merck is truly a 50-50 profit share partnership. Merck and Moderna will co-market the product in the United States, and Merck is fully responsible for commercialization outside of the United States.

Andrew Tsai, Analyst — Jefferies

I see. And then what other countries are you and Merck filing to next, and when does that happen?

David Berman, Other

So, I don't think we've disclosed where the global filing will be. Right now, we're focused on the U.S.

Andrew Tsai, Analyst — Jefferies

Got it. And, um... I asked you last week, but I'll ask again, is just, you know, we need to shore up our models on how this is going to be booked on the Moderna line. So how do you recognize this on the P&L?

Speaker 2

So we're still discussing that with our auditors as well as Merck and their auditors. There is a scenario where we, because we manufacture the product, that we do pre-booking in terms of the sales that will get, will be part of our revenue line. However, that's still being worked out with our auditors.

Andrew Tsai, Analyst — Jefferies

Okay, and then do you book, in terms of revenue, INT-only revenue or INT-plus PD-1 revenue?

Speaker 2

It's INT-only.

Andrew Tsai, Analyst — Jefferies

Okay. And gross margins, COGS, how should we think about that initially? Some people wonder if this is going to be like a cell therapy launch, high COGS, low margins. Can you walk us through how you're thinking about that and where does that go at steady state once you scale?

Speaker 2

So over the long term at Steady State, we expect to have very attractive margins for this product. We do not anticipate this looking like cart T, either at launch or over time, definitely not.

Andrew Tsai, Analyst — Jefferies

Got it. And then pricing bookends for INT, what should be some of the analogs we can gravitate or look at?

Speaker 2

So a little premature to talk about pricing. Typically what our partner Merck has done in the oncology setting is that we'll set pricing upon launch. Just to help on modeling. It's a very large range, but you can think of our proposition of a value proposition in terms of pricing, and the range maybe you could think through is low-end Keytruda-like pricing, and high-end other analogs in the market include individualized therapies like cell therapy. That's a very broad range. Somewhere in between that range could be a reasonable estimate.

Andrew Tsai, Analyst — Jefferies

Thank you. And so... As for the application itself, because you're using this kind of proprietary, unique AI algorithm, does that require some kind of special approval on top of the drug side? Maybe talk to them.

David Berman, Other

Yeah, so the algorithm, the proprietary algorithm, is part of the drug manufacturer, and so it does need to have FDA review as part of the CMC approval.

Andrew Tsai, Analyst — Jefferies

Okay. And as we think about you building out a moat for INT, can you talk about why other AI competitors won't be able to catch up or beat you guys?

David Berman, Other

The most important thing in an algorithm is linking it to efficacy. That's the single most important thing. There are a lot of algorithms out there, and they can generate T-cell reactivity, but you never know if it's going to be efficacious or not. And so, number one, we know that our current algorithm works, and that algorithm is proprietary. Number two is we now, with efficacy data in hand, we can go build a version two. We are using artificial intelligence as well. But we can build a version two by linking back to what makes a quality neoantigen, not just any neoantigen. So I think that we currently have a large moat, and I think we're going to, with so many ongoing randomized phase two and phase threes, nine of them, We're going to build up the world's largest database on what makes an effective neoantigen. I think it's going to be hard to overcome.

Speaker 2

Yeah, and that data really needs some emphasis because it is proprietary data that we will have that will then inform the algorithm version 2.0, version 3.0. And so from a competitive standpoint, it's that data that's going to inform the selection of the neoantigens. The other important thing to consider here in terms of a mode is that we took the strategy of starting in the adjuvant setting, and the studies that we're running is against the standard of care. So in melanoma, for instance, it's against... Pembrolizumab or Keytruda. And if we do then become the next standard of care, the combination of intismiram plus Keytruda, these studies in the adjuvant setting can take multiple years to read out. A competitor coming to market would have to use us as the control arm, which can also be cumbersome.

Andrew Tsai, Analyst — Jefferies

I see. And then maybe shifting gears to the next readout, RCC year-end, 2026 or early 2027. Are you guys using the same algorithm for that one, as well as for the other programs, actually?

David Berman, Other

Yeah, we are using the same algorithm. It's the algorithm that works for melanoma, and it should work for other tumors as well. So it is the same algorithm.

Andrew Tsai, Analyst — Jefferies

I see. I see. To the extent you are willing to share, if the interim, as we think about the scenarios of the interim, if it does not hit STAT-SIG this time, does the study continue, or is there futility?

David Berman, Other

Yeah, the study will continue. It's an interim for efficacy, not for futility.

Andrew Tsai, Analyst — Jefferies

Got it. And so, obviously, if it hits STAT-SIG, I think you'll announce that for sure immediately if it does not. Do you announce that immediately?

David Berman, Other

So this is an interim on a phase two, and I think we're in discussions with Merck on exactly how would we announce it, because it is a phase two interim. It's not a phase three interim.

Andrew Tsai, Analyst — Jefferies

Okay, and I think you guys have done a good job elucidating why you feel confident in RCC, but can you just remind us all the pieces of evidence that has led you to why you feel confident?

David Berman, Other

Yeah, sure, Andrew. So first of all, RCC is a T-cell sensitive tumor. We know cytokines work, and we know that immunotherapy works here. Our mechanism is to generate novel T-cells, checkpoints to reactivate T-cells. That's what we've learned from melanoma, so that's point number one. We can generate novel T-cells that the patient doesn't even have. Number two is there's a very nice paper out from Dana-Farber looking at personalized cancer vaccine using peptides, using their own algorithm. But on average, in using their algorithm, they identify 45. Quality neoantigens. And so I think that's a good surrogate. Now, we have a different algorithm, and we haven't disclosed how many we identified, but I think the fact that it's above 34, which is what goes into our cassette. I think that's a hopeful sign. Number three is our tumor mutational burden analysis from our randomized phase two. We had a similar efficacy in the phase two, whether it was high or low TMB, and that low TMB bracket overlaps with RCC. And then finally, the thing that was most compelling to me is the treatment effect that we saw in our phase three melanoma trial. So here it was 0.58 hazard ratio, so 42% improvement. Which is essentially what Keno54 showed in the adjuvant melanoma trial. And then, of course, we know that PEMBRO went on to work in RCC, bladder, lung, etc. And so we feel there's a lot of headroom left, given our benefit. And I'll add, our top line, our ITT, of course, was 0.58 hazard ratio. But our modified ITT, that is patients who actually received the blinded vaccine or the control, that has a ratio of 0.51. That, to me, represents the true treatment effect. So this is a really powerful treatment effect in melanoma. So those are the reasons I'm optimistic about RCC.

Andrew Tsai, Analyst — Jefferies

And then you mentioned just now the TMB in Phase 2 as one piece of evidence. Have you done that analysis in Phase III, as well as CTDNA, BRAF, subgroups, and what are you seeing?

David Berman, Other

Yes, so those were all the interesting insights we made in Phase II, and they are now in process for the Phase III trial, and we'll share those data when they're ready.

Andrew Tsai, Analyst — Jefferies

Okay. And for RCC... What's the minimum number of months of follow-up these patients will have?

David Berman, Other

Well, I can tell you now that, you know, we finished enrolling that sometime last year, I think, in the summer. Yeah, so now it's already been, you know, over 13, 14 months. So it's going to be long enough to go past whatever theoretical, you know, delayed separation that could happen. So I think that's hopeful. And then the minimum follow-up will be whenever the events get analyzed.

Andrew Tsai, Analyst — Jefferies

Thank you. Thank you. And so do you guys have an internal bar with Merck? What kind of efficacy do you want to see? This is a combo versus PD-1. I think there's HIF-2 combo versus PD-1. Is that the bar or not necessarily?

David Berman, Other

Yeah, not necessarily. So just as a reminder, Belzutifan plus Pembro had a hazard ratio around, I think, 0.72 or 0.73. And it does come with some HIF2-specific adverse events like hypoxia and anemia. Our intusmaren comes with, you know, very manageable, mostly mild adverse events, as I mentioned, of injection site pain and some mild fever. So I think there is that efficacy out there, but we also have a very favorable safety profile compared to Belzutapen.

Andrew Tsai, Analyst — Jefferies

Yeah, and I was just thinking in my head, we're discussing, you know, the original phase one, there was a basket study, but I noticed, I don't believe you guys tested in RCC. The question would be why not at the time?

David Berman, Other

Yeah, so RCC was not part of the original basket trial. You know, it included, I think, the typical tumors, the bladder, lung, and melanoma trials that historically have been very immunosensitive. But I wasn't here 10 years ago to know why RCC wasn't included. But I think based on what I know now, I am optimistic this can work in RCC.

Andrew Tsai, Analyst — Jefferies

Yes, understood. Okay, and so then moving on to the second INT readout coming up, bladder. Remind us the standard of care. I think this is also combo versus PD-1 alone. What is that efficacy threshold that you want to see, ultimately?

David Berman, Other

Yeah, so MIBC, just as a reminder, the trial design, it's randomizing to intizmaran plus pembrolizumab versus pembrolizumab after removal of the bladder. Now, here, the standard of care has changed since the trial started because now you have EV plus pembrol in the neoadjuvant setting. And, in fact, by the way, we do have a cohort of EV plus pembrol plus intizmaran as a just trial combination, neoadjuvant-adjuvant. And because we anticipated with Merck that EV might become the standard of care. So we do have a separate cohort. It's not part of the randomized trial. And so EV plus PEMBRO was not included, obviously, in our trial design. So that standard of care has changed. You also have atezolizumab in CT DNA positive after resection. So that was not, obviously, included in our trial. Although we did stratify by ctDNA because we did anticipate that ctDNA would be important. So I think that there has been changes since the original trial was designed, and I think we'll look at the treatment effect that comes out of here to determine what exactly the next Phase III study would look like.

Andrew Tsai, Analyst — Jefferies

I see. So there could be a chance that you ultimately run a head-to-head type study or not necessarily?

David Berman, Other

I think that there are multiple options because of the changing landscape. So if you look at what other companies have looked at, we could consider a triplet neoadjuvant, so EV plus Pembro. I think EV plus Pembro needs to be the backbone in the neoadjuvant just based on the data. But then there's a question in patients who receive EV plus Pembro and do not have a pathologic complete response. There might be a chance for intismarin in non-pathologic complete response. So I think that more needs to, you know, we'll need to see the treatment effect size and what the landscape looks like next year.

Andrew Tsai, Analyst — Jefferies

Yeah. And then I think we discussed earlier lung could be year-end, 2027, 2028. Remind us, what exactly is this subgroup for lung? Is it the intrapath OO2 that just didn't enroll in?

David Berman, Other

That's a big study, right? Yes, it's a big study. Phase three. It's a randomized phase three. It's in patients. We have three phase three trials in lung adjuvant. So we have the InterPath 002, which is patients who never received any neoadjuvant therapy, randomized to Pembro plus Intisram versus Pembro. That study completed randomization this year, very fast and rolling trial. And that's the one that events could happen at the end of next year, 27, or into 28. We have another trial in the adjuvant setting, patients who received neoadjuvant, PEMBRO plus chemo, but did not have a pathologic complete response, which is most patients in that setting. That trial is still enrolling. And then a third one that I'm really excited about, which is in stage one, lung cancer. So this is the earliest where, for the most part, the... Standard of care is observation, so you wait and watch until the patient relapses. And so here we're testing intespirant monotherapy as one of the experimental arms. I see.

Andrew Tsai, Analyst — Jefferies

Okay. And then I think as we continue to think about the various pieces of evidence, back at ESMO, you guys did actually have a pancreatic readout. I think it's INT plus pulferinox. What did you see there, and should that have read across to these upcoming INT readouts?

David Berman, Other

Number one is we were able to manufacture cassettes. In over half the patients, there was a full 34 neoantigens put in, which I think is pretty remarkable. Every patient had a T cell responding to at least one neoantigen, and you could combine it with fulthyrinox, and after fulthyrinox ended, we still had higher T cell reactivity than compared to baseline. So this can be studied in adjuvant. It was just too small, and the follow-up is not long enough to know if there's any efficacy signal.

Andrew Tsai, Analyst — Jefferies

I see. And one more is just the competitor front. For instance, I guess I get asked on BioNTech, and so why do you think you are the superior? Personalized vaccine.

David Berman, Other

So there's a, right, I mean, I don't want to say superior. I think we're the one that has demonstrated efficacy in a randomized phase three trial. I think there's some scientific. Platform differences. We use 34 neoantigens. They use 20. We use the same LNP that we use for COVID, inject it into the muscle, and we know it goes into the draining lymph node. They inject it intravenously, and it goes to the spleen. We don't know what their algorithm is, but we know that our algorithm has produced efficacy benefit, and our turnaround time has been faster than their reported turnaround time. So I think that those are the differences, but, you know, we have the randomized trial.

Andrew Tsai, Analyst — Jefferies

Right, and I think you guys have taken a data-led approach, because in the phase one, you did test colorectal already, and you didn't want to choose to enroll.

David Berman, Other

I still think colorectal is something that needs to be explored at the right time.

Andrew Tsai, Analyst — Jefferies

Okay, yep. And so to tie everything together, you're really, to me, I feel like going all in on INT. I think you've once guided 2028 to break even. Is that still the case by chance? But no worries.

Speaker 2

So we just had our analyst day, as you know, Andrew, and what we said at the analyst day is that our infectious disease vaccines portfolio, that business is on its way to profitability. And we expect that business to fund and sustainably fund itself, so any new infectious disease programs that will start will be funded by the cash flows in that business. But with this remarkable result in TISMORAN, we do now have a balance sheet that is $9 billion strong at the end of this year that will fund the growth in oncology. So the continual progress in the program, that development program we have ongoing, and any new programs or development that we do there.

Andrew Tsai, Analyst — Jefferies

Perfect. I think that's all the time we had, but thank you for all the insights and updates, and thanks, everyone, for listening.

Speaker 2

Thank you. Thank you.